Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 514 participants.
Also called NCT02787551
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 514 participants
- Sponsor
- Registry
-
NCT02787551
-
- Other papers using this trial's data
- Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes
- Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Estonia, Germany, Israel, Italy, Romania, Slovakia, Spain
- Registry status
- Completed
Technical summary
Registry record NCT02787551. Randomized; no masking; primary purpose treatment. Start 2016-07-06 (actual); primary completion 2018-05-25 (actual). Results posted on 2019-06-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
- Acronym
- LixiLan-G
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Insulin glargine/lixisenatide fixed ratio combination
- Intervention (Drug)
- liraglutide
- Intervention (Drug)
- exenatide
- Intervention (Drug)
- exenatide extended-release
- Intervention (Drug)
- albiglutide
- Intervention (Drug)
- dulaglutide
- Intervention (Drug)
- Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct02787551- Content hash
c67b6c8b066b2b04547fc87b66535906f8481281385dcdf9e990356a922e70f7